Trial Search Results

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Albert Koong

Stanford Investigator(s):


  • Radiation: Stereotactic Body Radiotherapy
  • Drug: Gemcitabine
  • Other: 4D pancreatic protocol CT scan
  • Radiation: FDG PET scan


Phase 2


Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension

   - Histologically confirmed malignancies of the pancreas

   - Unresectable by CT criteria or exploratory laparotomy or laparoscopy

   - Patients with metastatic disease may be treated if they are symptomatic from the
   primary tumor

   - Performance status of 0, 1, or 2

   - No chemotherapy two weeks prior or two weeks following radiosurgery

Exclusion Criteria:

   - patients who have had prior radiotherapy to upper abdomen

   - patients receiving any prior pancreatic cancer therapy

   - children, pregnant, and breastfeeding women, and lab personnel are excluded

   - uncontrolled intercurrent illnesses

   - any concurrent malignancy

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jeff Kim
Not Recruiting